Post-traumatic stress disorder symptoms following psychedelic use: a naturalistic survey study

Previous survey studies and qualitative reports have suggested that, although many psychedelic experiences are brief and manageable, a subset of users report persistent adverse psychological effects lasting months or years. However, those earlier studies mainly described broad symptom patterns rather than testing whether these longer-lasting difficulties could meet formal diagnostic criteria for post-traumatic stress disorder (PTSD). The paper also notes that challenging psychedelic states may involve intense fear, loss of control, resurfacing of traumatic memories, or distressing events occurring while intoxicated, any of which might plausibly contribute to post-traumatic stress symptoms. Evens and colleagues therefore aimed to examine whether enduring difficulties after a highly challenging psychedelic experience could meet DSM-5 PTSD criteria at the individual level, what participants considered the traumatic event to be, and how features of the acute experience related to later symptoms. They also explored post-traumatic growth and coping strategies, including which forms of help participants found useful. The study is presented as the first systematic investigation of PTSD-like outcomes following psychedelic use in a naturalistic sample.

Evens and colleagues conducted a cross-sectional online survey called the Study on Traumatic Experiences Related to Psychedelics in English and German. Data collection ran from 8 April 2024 to 15 November 2024, with ethics approval from Humboldt-Universität zu Berlin. Recruitment used convenience sampling through social media, online forums, newsletters, and psychedelics-related interest groups. Eligible participants were adults aged 18 years or older who had used a psychedelic substance at least once and who reported a particularly challenging or traumatic psychedelic experience that continued to affect them after the acute drug effects had ended. The survey encompassed classical psychedelics such as psilocybin, LSD, ayahuasca, mescaline, DMT, and 5-MeO-DMT, and also atypical substances including MDMA, ketamine, and cannabis, as reflected in the recruitment wording. The survey collected demographic information and detailed data on the index experience, including substance used, dose intensity, acute effects, duration, valence, setting, support present, prior psychedelic experience, later use, and motives for use. Participants indicated whether the experience mainly involved frightening thoughts or perceptions, recall of past traumatic memories, or a threatening/dangerous event. Those reporting memories or external events completed the Life Events Checklist for DSM-5. The study also used the Challenging Experience Questionnaire to assess acute distress, the Acceptance/Avoidance-Promoting Experiences Questionnaire to capture acceptance- and avoidance-related acute experiences, the PTSD Checklist for DSM-5 to assess post-traumatic stress symptoms, and the Post-Traumatic Growth Inventory to assess positive psychological change. For the PTSD classification, participants were placed in the PTSD group only if they self-reported symptoms across all four DSM-5 symptom clusters, exceeded the PCL-5 cut-off of 32, reported symptoms lasting more than 1 month, and said the symptoms caused clinically significant distress or functional impairment. This was based on self-report rather than a clinical interview. The researchers also excluded poor-quality responses using speed and free-text criteria. Analyses included descriptive comparisons between groups, principal component analysis of 22 use motives, and linear and multiple regression models predicting PTSD and post-traumatic growth from acute experience measures. Statistical significance was set at p < .05.

A total of 1,195 people started the survey, 512 gave consent, and 243 were included in the final analysis after exclusions for ineligibility, incomplete PTSD measures, or poor-quality responses. Nearly all participants reported at least one PTSD symptom on the PCL-5, and 31.3% met the study’s full self-report definition of PTSD. In the PTSD group, mean PCL-5 severity was 55.63, well above the clinical cut-off. Compared with the non-PTSD group, participants classified as PTSD were younger, had lower educational attainment, and were more likely to report a new mental health diagnosis following the psychedelic-related experience. They also reported greater current distress and longer symptom duration, and there was a non-significant trend towards lower post-traumatic growth. Most participants identified LSD or psilocybin as the main substance involved. About one-third reported more than one substance, and 56.3% of those with multiple substances said the combination involved LSD, psilocybin or MDMA with cannabis. Most index experiences had occurred more than 6 months earlier, and acute effects were usually described as strong or very strong. Calm indoor settings were most common, and about one-third said the setting had been prepared for a therapeutic aim. The PTSD group reported more concomitant substance use than the non-PTSD group and rated the index experience more negatively in retrospect. Use motives, reduced by principal component analysis, formed three components: hedonic intention, self-exploration intention, and escapist intention. PTSD and non-PTSD groups did not differ significantly on hedonic intention, but the PTSD group was described elsewhere in the paper as more likely to endorse escapist motives and less likely to endorse self-exploratory intentions. Regarding the index experience itself, 88.5% reported very challenging or frightening thoughts, perceptions, or feelings; 30.5% recalled challenging or traumatic past experiences; and 11.1% reported a threatening or dangerous event during intoxication. Around one-third endorsed more than one description. The acute experiences were rated as very challenging on the Challenging Experience Questionnaire by all participants, and avoidance-related experiences outweighed acceptance-related ones on the APEQ; both patterns were significantly stronger in the PTSD group. Among those whose distress centred on memories, many recalled sexual assault or other early-life traumatic events, and 44.8% said they had had no prior memory of the event. Confidence that the memory was real was high among those with prior memories and lower among those without them. Among those who identified an external threatening event, reports included assault, accidents, sexual assault, arrest, police contact, chaotic or threatening encounters with other intoxicated individuals, and unconsented actions by practitioners. Some reported that the substance increased perceived danger, while others said it reduced it. The open-text responses illustrated persistent symptoms such as anxiety, flashbacks, derealisation, depersonalisation, nightmares, panic attacks, dissociation, suicidal thinking, and functional impairment, sometimes lasting years. In regression analyses, higher Challenging Experience Questionnaire scores significantly predicted higher PTSD symptom severity (R² = .263). In the model using APEQ scores, avoidance-related experiences predicted higher PTSD symptoms, acceptance-related experiences predicted lower symptoms, and the interaction term was not significant (R² = .131). For post-traumatic growth, challenging experience severity was not associated with growth, but acceptance-related experiences strongly predicted higher growth (R² = .262); avoidance and the interaction term were not significant. Help-seeking was common: 65.0% of the whole sample and 85.1% of the PTSD group reported trying to address their symptoms. Participants commonly sought information online or spoke with friends and family, but psychotherapy was rated as the most helpful approach. The PTSD group also reported a wider range of other supports, including inpatient treatment, acupuncture, breathwork, hypnosis, ice bathing, exercise, electroconvulsive therapy, and specific psychotherapies such as EMDR and CPT.

The authors argue that the study provides systematic evidence that some people can develop clinically significant post-traumatic stress symptoms after challenging or traumatic psychedelic experiences. They emphasise that the 31.3% figure applies only to this self-selected sample of people who already reported persistent difficulties, and should not be treated as a prevalence estimate for all psychedelic users. They nevertheless suggest that psychedelic-related harms are not invariably mild or transient and may sometimes be long-lasting and severe. Evens and colleagues interpret the findings as showing that the intensity of the acute psychedelic experience matters, but that the psychological quality of that experience matters too. Avoidance-related experiences were linked to greater later PTSD symptoms, whereas acceptance-related experiences were linked to less post-traumatic stress and more post-traumatic growth. The authors present this as evidence that how a difficult experience is processed in the moment may be more important than difficulty alone. They also note that many participants reported help-seeking, yet psychotherapy was the most helpful intervention, which they see as consistent with established PTSD treatment principles. In discussing what counted as the traumatic event, the authors propose three pathways: an overwhelmingly frightening psychedelic state itself, the resurfacing of autobiographical traumatic memories, and external traumatic events occurring while intoxicated. They stress that some participants described memories of childhood sexual abuse that had not been previously recalled, while others described externally occurring threats that did not always fit conventional DSM-5 Criterion A events. They acknowledge that this is controversial, but argue that such cases can still be clinically relevant because the subjective experience of threat may be sufficient to produce lasting distress. The paper highlights several limitations. The sample was self-selected, largely middle-aged, male, Western, and relatively well educated, which restricts generalisability. The survey used self-report rather than a clinical interview, so some PTSD cases may have been overestimated or better explained by other diagnoses. The survey also included different substances, but there were too few atypical psychedelic cases for meaningful subgroup analyses. The authors further note that they did not assess the full breadth of psychedelic phenomenology, so their data cannot speak to other acute effects. They call for structured clinical interview studies, more work on memory processes and possible false memories, and better culturally sensitive and internet-based support resources for affected people.

The authors conclude that challenging or traumatic psychedelic experiences can be followed by later Criterion A PTSD symptoms in a subset of individuals, and that this may arise not only from the intensity of the acute experience but also from autobiographical memories or external distressing events occurring under the influence of psychedelics. They state that acceptance-related processing during the acute state may be especially important, and they emphasise the need for trauma-informed care and balanced harm-reduction approaches alongside ongoing psychedelic research and therapy.